1. Home
  2. GMRS vs CSTL Comparison

GMRS vs CSTL Comparison

Compare GMRS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GMRS

GMR Solutions Inc. Class A Common Stock

N/A

Current Price

$12.67

Market Cap

781.0M

ML Signal

N/A

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$33.40

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GMRS
CSTL
Founded
N/A
2007
Country
United States
Employees
N/A
N/A
Industry
Transportation Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.0M
722.8M
IPO Year
2026
2019

Fundamental Metrics

Financial Performance
Metric
GMRS
CSTL
Price
$12.67
$33.40
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
749.5K
492.9K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
N/A
$2.42
Revenue Next Year
N/A
$12.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$11.90
$17.72
52 Week High
$15.98
$44.28

Technical Indicators

Market Signals
Indicator
GMRS
CSTL
Relative Strength Index (RSI) 46.09 63.27
Support Level $12.06 $22.88
Resistance Level $13.36 $33.75
Average True Range (ATR) 0.96 1.74
MACD -0.05 0.04
Stochastic Oscillator 30.99 75.93

Price Performance

Historical Comparison
GMRS
CSTL

About GMRS GMR Solutions Inc. Class A Common Stock

GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: